Acute coronary syndrome (ACS) is a multi-factorial condition with a strong inflammatory component, which is immune-mediated by chemokines. The CCL5 is a chemokine that has been suggested to be an important participant in the development of the atherosclerotic plaque. Therefore, in this work, we evaluated whether three polymorphisms located in the promoter region of the CCL5 gene [CCL5 -28 G/C (rs2280788), CCL5−109 G/A (rs1800825), and CCL5−403 G/A (rs2107538)] are significantly associated with the acute coronary syndrome (ACS), and plasma CCL5 levels. The determination of the gene polymorphisms was performed by 5′exonuclease TaqMan assays in 625 patients with ACS and 700 control individuals. Plasma CCL5 levels were evaluated by ELISA. Under co-dominant, dominant, and additive models, the G allele of the -109 G/A polymorphism was associated with a higher risk of ACS (OR = 1.27, pC_Co-dom = 0.041, OR = 1.33, pC_Dom = 0.03, and OR = 1.33, pC_Add = 0.015, respectively). In the same way, under co-dominant and recessive models, the A allele of the -403 G/A polymorphism was associated with an increased risk of ACS (OR = 1.62, pC_Co-dom = 0.042, and OR = 1.63, pC_Res = 0.012, respectively). The CCL5−109 G allele carriers had a lower concentration of the CCL5 than subjects with the A allele. Also, carriers of CCL5−403 A allele showed a lower concentration of the CCL5 than individuals with the G allele. Our data suggest the association of the CCL5−109 G/A and CCL5−403 G/A polymorphisms with the risk of developing ACS and with a lower concentration of CCL5 in our population.

急性冠脉综合征 (ACS) 是一种多因素疾病，具有强烈的炎症成分，由趋化因子免疫介导。CCL5 是一种趋化因子，已被认为是动脉粥样硬化斑块发展的重要参与者。因此，在这项工作中，我们评估了位于CCL5基因 [ CCL5 -28 G/C (rs2280788)、CCL5−109 G/A (rs1800825) 和CCL5−403 G/A(rs2107538)] 与急性冠状动脉综合征 (ACS) 和血浆 CCL5 水平显着相关。在 625 名 ACS 患者和 700 名对照个体中，通过 5' 核酸外切酶 TaqMan 测定法确定基因多态性。通过ELISA评估血浆CCL5水平。在共显性、显性和加性模型下，-109 G/A多态性的G等位基因与更高的 ACS 风险相关（OR = 1.27，pC _Co-dom = 0.041，OR = 1.33，pC _Dom = 0.03 ，和 OR = 1.33 ，分别为pC _Add = 0.015）。同理，在共显性和隐性模型下，-403 G/A的A等位基因多态性与 ACS 风险增加相关（分别为 OR = 1.62，pC _Co-dom = 0.042 和 OR = 1.63，pC _Res = 0.012）。所述CCL5-109ģ等位基因携带者的CCL5大于与受试者的较低浓度甲等位基因。此外，CCL5-403 A等位基因携带者的 CCL5 浓度低于具有G等位基因的个体。我们的数据表明CCL5-109 G/A和CCL5-403 G/A多态性与我们人群中发生 ACS 的风险和较低的 CCL5 浓度相关。